HLX-22

Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant upside in 2026. Mitazalimab validation: OPTIMIZE-1 biomarker results published in Cell Reports Medicine and REACtiVe-2 data in Nature Communications. Pipeline progress: U.S. patent granted for ATOR-4066, supporting long-term value beyond the lead program. LUND, SE / ACCESS Newswire / February 12, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced its interim results for the third quarter of 2025 and provided a business update. "The fourth quarter of 2025 was marked by continued execution on our strategy, focusing on advancing mitazalimab towards initiation of registrational trials, strengthening the scientific foundation of our pipeline, and increasing financial flexibility. While the external funding environment for biotech remains challenging, we have concentrated on areas within our control - generating high-quality data, maintaining operational discipline, and making focused investments that position the company to progress mitazalimab toward late-stage development." Søren Bregenholt, CEO of Alligator Bioscience BUSINESS UPDATE Mitazalimab Scientific validation: Biomarker analyses from OPTIMIZE-1 were published in Cell Reports Medicine , deepening the understanding of mitazalimab's mechanism of action and links to clinical outcomes. Additional clinical publication: Data from the Phase 1 REACtiVe-2 study were published in Nature Communications , supporting mitazalimab's ability to activate systemic immune responses in metastatic pancreatic cancer. External visibility: Mitazalimab data were presented at international scientific congresses during the quarter, further strengthening clinical relevance and scientific recognition. ATOR-4066 Pipeline progress: Preclinical and mechanistic data for ATOR-4066 were presented at international scientific meetings, supporting its immune-modulating potential as a next-generation bispecific antibody program. Strengthened intellectual property: A U.S. patent covering ATOR-4066 was granted, reinforcing long-term protection and supporting the program's future value. HLX22 Program expansion: Henlius received approval to initiate Phase 2/3 studies in breast cancer in China, broadening the clinical scope of HLX22 and potentially increasing the opportunity for future milestone payments and royalty revenues for Alligator. Company / Financial position Rights issue completed: Alligator finalized a rights issue of units (shares and warrants) to strengthen its financial position and support continued development of mitazalimab. Outcome announced 22 December: The issue was subscribed to approximately 64.8%, providing around SEK 91 million (gross) before issue costs and repayments. Additional capital potential in 2026: The rights issue included warrants that may provide further funding next year, supporting continued flexibility. Bridge financing and loan repayment: The rights issue followed bridge financing to secure near-term liquidity and enabled repayment of bridge loans and part of the outstanding loan to Fenja Capital. FINANCIAL SUMMARY FOR Q4 AND YEAR-END 2025 The financial summaries for the quarterly periods ending 31 December 2025 and 31 December 2024 are presented below. All amounts in MSEK, unless specified October - December 2025 October - December 2024 Net sales - 41.8 Operating profit/loss -22.5 -60.1 Profit/loss for the period -29.0 -55.4 Cash flow for the period 37.2 17.1 Cash and cash equivalents 62.2 64.3 Earnings per share before and after dilution*, SEK -0.66 -73.10 * Adjusted for reverse share split. The financial summaries for the year-to-date periods ending 31 December 2025 and 31 December 2024 are presented below. All amounts in MSEK, unless specified January - December 2025 January - December 2024 Net sales 0.5 57.8 Operating profit/loss -105.8 -229.1 Profit/loss for the period -51.4 -233.9 Cash flow for the period -1.2 -1.2 Cash and cash equivalents 62.2 64.3 Earnings per share before and after dilution*, SEK -1.87 -318.53 * Adjusted for reverse share split. The full report is attached as a PDF, and is also available on the company's website: Alligator will host a webinar on Thursday, 12 February 2026, at 3 p.m. CEST/ 9 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report, which will be followed by a Q&A session. The call will be held in English. Attendees need to register by following >>this link<< . For further information, please contact: Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com Phone: +46 (0) 46 540 82 00 Johan Giléus, CFO E-mail: johan.gileus@alligatorbioscience.com Phone: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on 12 February 2026. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments 2025 Q4 EN VF SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held in San Francisco, the United States, from January 12 to 15. On January 15 (PST), Dr. Jason Zhu, Executive Director and Chief Executive Officer of Shanghai Henlius Biotech, Inc. (2696.HK), delivered a keynote presentation outlining Henlius' "Globalisation 2.0" strategy, diversified innovation pipeline, and its mid-to-long-term development blueprint. The Company's international business continues to grow at a rapid pace. Looking ahead to 2030, Henlius anticipates to launch more than 20 products globally, including over 15 products in the U.S. and European markets. Dr. Zhu highlighted Henlius' continuous growth trajectory and phased achievements under its "Globalisation 2.0" strategy: "With multiple products approved successively in Europe and the United States, and an increasingly mature integrated global operating model, our international business has maintained strong growth momentum. Leveraging our integrated R&D, regulatory and manufacturing capabilities, together with an increasingly mature global clinical and commercialisation network, we have established a systematic capacity to continuously deliver innovative assets worldwide. Over the next five years, stable cash flows from our biosimilar portfolio will further support innovation investment, enabling the advancement of more differentiated molecules, including ADCs, multi-Abs and TCEs, into global markets and building a sustainable, replicable globalisation growth model." Henlius also outlined clear timelines and development plans for its key innovation assets in 2026, including serplulimab (trade name: Hetronifly® in Europe), an anti-PD-1 mAb; HLX22, a novel epitope anti-HER2 mAb; HLX43, a PD-L1 ADC; and HLX07, an anti-EGFR mAb. At present, the Company's preclinical asset portfolio spans multiple molecular modalities, including antibodies, multispecific TCEs, ADCs, fusion proteins and small molecules, with a primary focus on solid tumors. Its differentiated development strategy targets both established and emerging targets such as PD-(L)1, DLL3, B7-H3, HER2, EGFR, c-Met and KAT6A/B. The portfolio comprises a balanced mix of potential FIC and BIC candidates, as well as fast-follow programs with higher clinical and commercialisation certainty, laying a solid foundation for the sustained advancement of the mid- to long-term clinical pipeline. By proactively structuring its preclinical portfolio to encompass diverse innovation profiles including FIC, BIC and fast-follow programs, the company has established a tiered R&D architecture that balances frontier innovation with development efficiency and risk management, thereby supporting the continuous progression of its innovation pipeline. 21% more press release views with Request a Demo